New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients
NCT ID NCT06648096
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called afatinib in 25 adults with Fanconi anemia who have advanced head and neck cancer that cannot be removed by surgery. Afatinib is a pill that blocks a protein helping cancer grow. The goal is to see if it can shrink tumors and control the disease. Researchers will monitor safety and tumor response over 9 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Afatinib
What this could lead to
If successful, this could provide a targeted treatment option to control head and neck cancer in people with Fanconi anemia, who have limited options.
What could go wrong
This is an early-phase, small trial (25 people) with no control group. Afatinib may not shrink tumors or could cause significant side effects, especially in this vulnerable population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, Catalonia, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Medizinische Hochschule Hannover
RECRUITINGHanover, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact